Skip to main content

Table 1 Patient characteristics in Mean (SD) or n (%) at baseline and measurements during surgery

From: Effect of baseline cognitive impairment on association between predicted propofol effect site concentration and Bispectral index or sedation score

Baseline characteristicsWith Ce (n = 186)Without Ce (n = 14)
Before surgery
 Age81.9 (7.8)79.8 (7.0)
 Mini-Mental Status Examination (MMSE)24.2 (3.7)25.1 (3.4)
 Geriatric depression scale score3.9 (3.6)3.0 (2.0)
 Clinical Dementia Rating (n = 184/14)
  075 (41%)7 (50%)
  0.588 (48%)6 (43%)
   ≥ 1.021 (11%)1 (7%)
 Charlson Comorbidity Score1.5 (1.7)2.0 (2.4)
  066 (35%)6 (43%)
  183 (45%)3 (21%)
  226 (14%)3 (21%)
   > 211 (6%)2 (14%)
Alzheimer’s cerebrospinal fluid biomarkers
 Total Tau, pg/ml (n = 164/6)490.8 (275.1)617.7 (435.7)
 Phosphorylated Tau (pg/ml (n = 163/6)56.7 (25.1)63.0 (32.9)
 Amyloid Beta 42 (pg/ml (n = 164/6)298.3 (164.1)281.2 (106.7)
 Amyloid Beta 42/Total Tau(n = 164/6)0.71 (0.38)0.61 (0.32)
 Amyloid Beta 42/Phosphorylated Tau (n = 163/6)5.75 (2.83)5.16 (2.29)
During surgery
 Observers Assessment Alertness/Sedation score2.2 (2.1)1.4 (2.1)
 Bispectral Index number (n = 183/13)69.1 (18.1)75.0 (13.7)
 Brain Effect Site Concentration, ug/ml1.26 (0.79)--- (−--)
 Mean Arterial Pressure73.4 (10.5)77.1 (11.8)
  1. CDR, Clinical Dementia Rating (0 = normal, 0.5 = mild cognitive impairment, ≥1 = dementia); MMSE, Mini-Mental Status Examination (maximum score of 30 points)